OraSure's (OSUR) OraQuick Receives Unanimous Recommendation from FDA Panel

Article Stock Quotes (1) Comments (0)

OraSure Technologies, Inc. (Nasdaq: OSUR) today announced that the U.S. FDA Blood Products Advisory Committee (BPAC) provided a unanimous positive recommendation for the Company's OraQuick^® In-Home HIV Test. The BPAC provides advice to the FDA on issues related to the safety and effectiveness of biological products and medical devices seeking FDA approval.

The BPAC voted on two questions posed by FDA:

• Do the projected benefits of the test outweigh the potential risks of false positive and false negative test results? The committee voted 17-0 in the affirmative to that question.
  
• Do the available data provide reasonable assurance that the test is safe and effective for its intended use? The committee voted 17-0 in the affirmative to that question.

In addition to reviewing the Company's clinical data and performance, the BPAC considered data presented by the FDA and testimonies shared during the public comment session. The committee also discussed risk mitigation strategies that should be considered in addition to the current proposed labeling.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Novo Nordisk (NVO) Reports Positive Results from Paradigm 2
• Sanofi (SNY) Reports JAKARTA Met Primary Endpoint in Both Groups
• St. Jude (STJ) Receives CE Mark for LUMIEN OPTIS PCI System

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?